Display options
Share it on

Chem Cent J. 2011 Jul 05;5:38. doi: 10.1186/1752-153X-5-38.

Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasma.

Chemistry Central journal

Ibrahim A Darwish, Abdul-Rahman M Al-Obaid, Hamoud A Al-Malaq

Affiliations

  1. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P,O, Box 2457, Riyadh 11451, Saudi Arabia. [email protected].

PMID: 21726466 PMCID: PMC3149564 DOI: 10.1186/1752-153X-5-38

Abstract

In this study, a polyclonal antibody with high avidity and specificity to the potent hypocholesterolaemic agent rosuvastatin (ROS) has been prepared and used in the development of highly sensitive enzyme-linked immunosorbent assay (ELISA) for determination of ROS in plasma. ROS was coupled to keyhole limpt hemocyanin (KLH) and bovine serum albumin (BSA) using carbodiimide reagent. ROS-KLH conjugate was used for immunization of female 8-weeks old New Zealand white rabbits. The immune response of the rabbits was monitored by direct ELISA using ROS-BSA immobilized onto microwell plates as a solid phase. The rabbit that showed the highest antibody titer and avidity to ROS was scarified and its sera were collected. The IgG fraction was isolated and purified by avidity chromatography on protein A column. The purified antibody showed high avidity to ROS; IC50 = 0.4 ng/ml. The specificity of the antibody for ROS was evaluated by indirect ELISA using various competitors from the ROS-structural analogues and the therapeutic agents used with ROS in a combination therapy. The proposed ELISA involved a competitive binding reaction between ROS, in plasma sample, and the immobilized ROS-BSA for the binding sites on a limited amount of the anti-ROS antibody. The bound anti-ROS antibody was quantified with horseradish peroxidase-labeled second anti-rabbit IgG antibody (HRP-IgG) and 3,3',5,5'-tetramethylbenzidine (TMB) as a substrate for the peroxidase enzyme. The concentration of ROS in the sample was quantified by its ability to inhibit the binding of the anti-ROS antibody to the immobilized ROS-BSA and subsequently the color intensity in the assay wells. The assay enabled the determination of ROS in plasma at concentrations as low as 40 pg/ml.

References

  1. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):35-40 - PubMed
  2. J Pharm Biomed Anal. 2007 Jun 28;44(2):540-6 - PubMed
  3. Atherosclerosis. 2006 Jan;184(1):233-4 - PubMed
  4. Atherosclerosis. 2009 May;204(1):208-15 - PubMed
  5. Anal Biochem. 1966 Mar;14(3):328-36 - PubMed
  6. Br J Clin Pharmacol. 2003 Jan;55(1):94-9 - PubMed
  7. Biomed Chromatogr. 2006 Sep;20(9):881-7 - PubMed
  8. Biomed Chromatogr. 2006 Mar;20(3):282-93 - PubMed
  9. J Pharm Biomed Anal. 2007 Jun 28;44(2):379-87 - PubMed
  10. Diabetologia. 2008 Sep;51(9):1731-40 - PubMed
  11. Biomed Chromatogr. 2006 Nov;20(11):1252-9 - PubMed
  12. Rapid Commun Mass Spectrom. 2006;20(16):2369-75 - PubMed
  13. Pharmacol Ther. 2007 Jan;113(1):184-96 - PubMed
  14. Clin Ther. 2004 Nov;26(11):1855-64 - PubMed
  15. Z Naturforsch C Biosci. 1981 May-Jun;36(5-6):459-63 - PubMed
  16. Int J Biomed Sci. 2006 Sep;2(3):217-35 - PubMed
  17. Clin Chem. 1989 Oct;35(10):2152-3 - PubMed
  18. Menopause. 2001 May-Jun;8(3):216-21 - PubMed
  19. Am J Cardiol. 2007 Mar 1;99(5):673-80 - PubMed
  20. J Pharm Biomed Anal. 2000 Jan;21(6):1249-73 - PubMed
  21. Am J Cardiol. 2003 Jun 1;91(11):1304-10 - PubMed
  22. Talanta. 2009 Oct 15;79(5):1478-83 - PubMed

Publication Types